What is the difference between Liraglutide and Cagrilintide?

Liraglutide (Liraglutide (Saxenda / Victoza)) is graded A+ and is FDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza). Cagrilintide (Cagrilintide (long-acting amylin analog)) is graded A and is Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress. They are commonly compared because they share the categories: weight-loss, metabolic.

Which has stronger clinical evidence — Liraglutide or Cagrilintide?

On our internal evidence scale, Liraglutide is A+ and Cagrilintide is A. A+ indicates large RCTs plus FDA approval; C indicates primarily preclinical or anecdotal evidence.

What is the typical dose of Liraglutide vs Cagrilintide?

Liraglutide: 0.6–3.0 mg daily (subcutaneous). Cagrilintide: Trial range: 0.16–4.5 mg weekly (subcutaneous). Always work with a licensed clinician — peptide dosing should be individualized.

Liraglutide vs Cagrilintide

Both Liraglutide and Cagrilintide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Liraglutide

Evidence A+

Liraglutide (Saxenda / Victoza)

The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.

View full Liraglutide profile →

Cagrilintide

Evidence A

Cagrilintide (long-acting amylin analog)

A once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.

View full Cagrilintide profile →

Side-by-Side

Attribute	Liraglutide	Cagrilintide
Evidence Grade	A+	A
FDA Status	FDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza)	Not FDA-approved — combined with semaglutide as CagriSema; Phase 3 in progress
Typical Dose	0.6–3.0 mg daily (subcutaneous)	Trial range: 0.16–4.5 mg weekly (subcutaneous)
Clinics Indexed	540	8
Categories	weight-loss, metabolic	weight-loss, metabolic

Key reported benefits — Liraglutide

✓Weight loss
✓Appetite suppression
✓Glycemic control

Key reported benefits — Cagrilintide

✓Amylin pathway weight loss
✓Synergy with GLP-1
✓Lower-dose tolerability

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons